• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BD provides Embecta spinoff update, plans for April 1 completion

March 21, 2022 By Sean Whooley

BD Diabetes Spinoff EmbectaBD (NYSE:BDX) announced today that it still expects the spinoff of its diabetes business — named Embecta — to complete on April 1.

Franklin Lakes, N.J.–based BD announced in May 2021 that it intended to spin off its diabetes care business as an independent, publicly-traded company during the first half of 2022, and in December 2021, it unveiled the name of the new business as “Embecta.”

BD’s board approved the Embecta spinoff last month, concluding that the separation of the diabetes business from the rest of BD is consistent with the company’s growth strategy and enhances the ability of Embecta to attract capital investment, recruit talent and allocate resources.

The company set a record date of March 22, 2022, for the distribution of shares of Embecta common stock. Each BD shareholder will receive one share of Embecta stock for every five shares of BD common stock held as of the close of business on March 22 once the spinoff completes.

“When issued” trading of Embecta common stock is expected to begin today under the “EMBCV” ticker, with “regular trading” of Embecta common stock set to commence on April 1 under the “EMBC” ticker on the Nasdaq market.

BD shareholders don’t need to take any action to receive the shares of Embecta common stock distributed through the spinoff.

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: BD, embecta

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS